Cargando…

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review

PURPOSE: To evaluate 6-month treatment benefits with lifitegrast ophthalmic solution 5% in symptomatic dry eye patients. SETTING: Retrospective chart analysis. METHOD: A retrospective chart review was conducted in 168 patients (111 females and 57 males) who presented with symptoms of chronic dry eye...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah, Richard Teofilo, Castanos, Maria Virginia, Najac, Richard, Donnenfeld, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590901/
https://www.ncbi.nlm.nih.gov/pubmed/31354236
http://dx.doi.org/10.2147/OPTH.S191635
_version_ 1783429650556387328
author Atallah, Richard Teofilo
Castanos, Maria Virginia
Najac, Richard
Donnenfeld, Eric
author_facet Atallah, Richard Teofilo
Castanos, Maria Virginia
Najac, Richard
Donnenfeld, Eric
author_sort Atallah, Richard Teofilo
collection PubMed
description PURPOSE: To evaluate 6-month treatment benefits with lifitegrast ophthalmic solution 5% in symptomatic dry eye patients. SETTING: Retrospective chart analysis. METHOD: A retrospective chart review was conducted in 168 patients (111 females and 57 males) who presented with symptoms of chronic dry eye disease and were treated with lifitegrast 5% ophthalmic solution for 6 months. Collected symptom data included improvement of eye dryness, tearing, eye pain, fluctuation in vision, foreign body sensation, itching, grittiness, burning and contact lens intolerance if applicable. Collected clinical signs included changes in superficial punctate keratitis, corneal fluorescein staining, conjunctival hyperemia and presence of tear debris. RESULTS: Treatment with lifitegrast ophthalmic solution 5% twice daily for 6 months significantly improved majority of dry eye symptoms reported by patients. Improvements were also observed in corneal and conjunctival staining and tear debris for most of the patients reviewed. CONCLUSION: Treatment with lifitegrast twice a day for 6 months improved both signs and symptoms of chronic dry eye.
format Online
Article
Text
id pubmed-6590901
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65909012019-07-26 Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review Atallah, Richard Teofilo Castanos, Maria Virginia Najac, Richard Donnenfeld, Eric Clin Ophthalmol Rapid Communication PURPOSE: To evaluate 6-month treatment benefits with lifitegrast ophthalmic solution 5% in symptomatic dry eye patients. SETTING: Retrospective chart analysis. METHOD: A retrospective chart review was conducted in 168 patients (111 females and 57 males) who presented with symptoms of chronic dry eye disease and were treated with lifitegrast 5% ophthalmic solution for 6 months. Collected symptom data included improvement of eye dryness, tearing, eye pain, fluctuation in vision, foreign body sensation, itching, grittiness, burning and contact lens intolerance if applicable. Collected clinical signs included changes in superficial punctate keratitis, corneal fluorescein staining, conjunctival hyperemia and presence of tear debris. RESULTS: Treatment with lifitegrast ophthalmic solution 5% twice daily for 6 months significantly improved majority of dry eye symptoms reported by patients. Improvements were also observed in corneal and conjunctival staining and tear debris for most of the patients reviewed. CONCLUSION: Treatment with lifitegrast twice a day for 6 months improved both signs and symptoms of chronic dry eye. Dove 2019-06-19 /pmc/articles/PMC6590901/ /pubmed/31354236 http://dx.doi.org/10.2147/OPTH.S191635 Text en © 2019 Atallah et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Rapid Communication
Atallah, Richard Teofilo
Castanos, Maria Virginia
Najac, Richard
Donnenfeld, Eric
Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
title Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
title_full Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
title_fullStr Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
title_full_unstemmed Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
title_short Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
title_sort six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590901/
https://www.ncbi.nlm.nih.gov/pubmed/31354236
http://dx.doi.org/10.2147/OPTH.S191635
work_keys_str_mv AT atallahrichardteofilo sixmonthstreatmentwithlifitegrastinpatientswithmoderatetoseveresymptomaticdryeyearetrospectivechartreview
AT castanosmariavirginia sixmonthstreatmentwithlifitegrastinpatientswithmoderatetoseveresymptomaticdryeyearetrospectivechartreview
AT najacrichard sixmonthstreatmentwithlifitegrastinpatientswithmoderatetoseveresymptomaticdryeyearetrospectivechartreview
AT donnenfelderic sixmonthstreatmentwithlifitegrastinpatientswithmoderatetoseveresymptomaticdryeyearetrospectivechartreview